John F. Crowley - 05 Oct 2021 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: Director
Signature: /s/James Basta, Attorney-In-Fact
Issuer symbol: NTLA
Transactions as of: 05 Oct 2021
Net transactions value: -$1,117,091
Form type: 4
Filing time: 07 Oct 2021, 17:41:15 UTC
Previous filing: 04 Oct 2021
Next filing: 13 Oct 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise	$188,300	+10,000	+478%	$18.83	12,094	05 Oct 2021	Direct
transaction	NTLA	Common Stock	Sale	$164,902	-1,280	-11%	$128.83	10,814	05 Oct 2021	Direct	F1, F2
transaction	NTLA	Common Stock	Sale	$378,600	-2,915	-27%	$129.88	7,899	05 Oct 2021	Direct	F1, F3
transaction	NTLA	Common Stock	Sale	$492,128	-3,759	-48%	$130.92	4,140	05 Oct 2021	Direct	F1, F4
transaction	NTLA	Common Stock	Sale	$243,192	-1,846	-45%	$131.74	2,294	05 Oct 2021	Direct	F1, F5
transaction	NTLA	Common Stock	Sale	$26,568	-200	-8.7%	$132.84	2,094	05 Oct 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Options Exercise	$0	-10,000	-26%	$0.000000	28,000	05 Oct 2021	Common Stock	10,000	$18.83	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.09 to $129.05, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.28 to $130.25, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.445 to $131.42, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.445 to $132.24, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 5, 2021 at each separate price.
F6	The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 12,666 shares as of October 5, 2021.